Primary neuroendocrine carcinoma of the breast: A single Center experience and review of the literature

Risultato della ricerca: Article

Abstract

Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies (Neuron-specific enolase, Chromogranin, Synaptophysin, Estrogen and Progesterone receptors, c-erb and Ki-67). All cases showed markers positivity to Neuron-specific enolase, Chromogranin, Synaptophysin and Estrogen and Progesterone receptors were found. Ki-67 was higher than 40% in four patients. Adjuvant chemotherapy was administrated in patients with Ki-67 > 10%; every patients were treated with radiotherapy and with hormonal therapy too. Although Neuroendocrine breast tumor is considered a distinct entity, the best treatment seems to be correlate to the size of tumor and to the lymph node status and to Ki-67 index like the common breast cancer.
Lingua originaleEnglish
pagine (da-a)116-121
Numero di pagine6
RivistaAnnali Italiani di Chirurgia
Volume88
Stato di pubblicazionePublished - 2017

Fingerprint

Neuroendocrine Carcinoma
Breast
Chromogranins
Synaptophysin
Phosphopyruvate Hydratase
Progesterone Receptors
Estrogen Receptors
Dissection
Breast Neoplasms
Neoplasms
Neuroendocrine Tumors
Neoplasm Staging
Mastectomy
Hematoxylin
Adjuvant Chemotherapy
Eosine Yellowish-(YS)
Radiotherapy
Therapeutics
Lymph Nodes
Antibodies

All Science Journal Classification (ASJC) codes

  • Surgery

Cita questo

@article{cb60dc075d6547c0ba80f74e0fd0a892,
title = "Primary neuroendocrine carcinoma of the breast: A single Center experience and review of the literature",
abstract = "Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies (Neuron-specific enolase, Chromogranin, Synaptophysin, Estrogen and Progesterone receptors, c-erb and Ki-67). All cases showed markers positivity to Neuron-specific enolase, Chromogranin, Synaptophysin and Estrogen and Progesterone receptors were found. Ki-67 was higher than 40{\%} in four patients. Adjuvant chemotherapy was administrated in patients with Ki-67 > 10{\%}; every patients were treated with radiotherapy and with hormonal therapy too. Although Neuroendocrine breast tumor is considered a distinct entity, the best treatment seems to be correlate to the size of tumor and to the lymph node status and to Ki-67 index like the common breast cancer.",
author = "Giuseppa Graceffa and Salvatore Vieni and Antonietta Grillo and Antona, {Angelo Danilo} and Paolo Locurto and Antonio Ciulla and Stefania Martorana",
year = "2017",
language = "English",
volume = "88",
pages = "116--121",
journal = "Annali Italiani di Chirurgia",
issn = "0003-469X",
publisher = "Edizioni Luigi Pozzi S.r.l.",

}

TY - JOUR

T1 - Primary neuroendocrine carcinoma of the breast: A single Center experience and review of the literature

AU - Graceffa, Giuseppa

AU - Vieni, Salvatore

AU - Grillo, Antonietta

AU - Antona, Angelo Danilo

AU - Locurto, Paolo

AU - Ciulla, Antonio

AU - Martorana, Stefania

PY - 2017

Y1 - 2017

N2 - Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies (Neuron-specific enolase, Chromogranin, Synaptophysin, Estrogen and Progesterone receptors, c-erb and Ki-67). All cases showed markers positivity to Neuron-specific enolase, Chromogranin, Synaptophysin and Estrogen and Progesterone receptors were found. Ki-67 was higher than 40% in four patients. Adjuvant chemotherapy was administrated in patients with Ki-67 > 10%; every patients were treated with radiotherapy and with hormonal therapy too. Although Neuroendocrine breast tumor is considered a distinct entity, the best treatment seems to be correlate to the size of tumor and to the lymph node status and to Ki-67 index like the common breast cancer.

AB - Neuroendocrine carcinoma of the breast is an extremely rare tumor. A standard treatment has yet to be established because only a few cases have been reported in literature. The authors report five cases observed from January 2007 to December 2014 and a review of literature. Four patients underwent quadrantectomy and in two cases axillary nodal dissection and only one to mastectomy with axillary nodal dissection. Tumor size was from T1 to T2 with N0 to N1, according TNM classification. Pathological specimens were stained with hematoxylin and eosin and an immunohistochemical panel of antibodies (Neuron-specific enolase, Chromogranin, Synaptophysin, Estrogen and Progesterone receptors, c-erb and Ki-67). All cases showed markers positivity to Neuron-specific enolase, Chromogranin, Synaptophysin and Estrogen and Progesterone receptors were found. Ki-67 was higher than 40% in four patients. Adjuvant chemotherapy was administrated in patients with Ki-67 > 10%; every patients were treated with radiotherapy and with hormonal therapy too. Although Neuroendocrine breast tumor is considered a distinct entity, the best treatment seems to be correlate to the size of tumor and to the lymph node status and to Ki-67 index like the common breast cancer.

UR - http://hdl.handle.net/10447/237317

UR - http://www.annaliitalianidichirurgia.it/PDF/ONLINE/2658_28_11_2016_EP_b.pdf

M3 - Article

VL - 88

SP - 116

EP - 121

JO - Annali Italiani di Chirurgia

JF - Annali Italiani di Chirurgia

SN - 0003-469X

ER -